Research programme: gastrointestinal therapeutics - enGene/Takeda
Latest Information Update: 28 May 2022
Price :
$50 *
At a glance
- Originator enGene; Takeda
- Class Anti-inflammatories; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammatory bowel diseases; Short bowel syndrome
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Canada (PO)
- 28 May 2022 No recent reports of development identified for preclinical development in Short-bowel-syndrome in Canada (PO)
- 06 May 2020 Preclinical development is ongoing in Canada (engene pipeline, May 2020)